SMARCC2

Across TCGA pan-cancer cohorts, SMARCC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMARCC2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMARCC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMARCC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and OV show a favorable association.

HNSC, LUAD, and OV are the cancer types where SMARCC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.687	0.897	.003	51	view →
LUAD	OS	Median	All	0.917	0.746	.006	12	view →
OV	DFS	Median	All	1.000	0.864	.035	4	view →
GBM	DFS	Tertile	All	0.415	0.266	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMARCC2–HNSC (DFS)

Open the HNSC breakdown →